Drug
Givosiran
Givosiran: highest development phase Phase 1, developed by Alnylam Pharmaceuticals. 1 trial record tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Alnylam Pharmaceuticals
Trials
| Drug | Phase | Indication |
|---|---|---|
| givosiran (ALN-AS1) NCT02452372 | Phase 1 | Acute Intermittent Porphyria |
Latest
No recent events.
Follow Givosiran on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.